Publication: 3388

Publication: 3388

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: NPJ Breast Cancer vol 8

Year:: 2022
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Meta-Analysis
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 11

Parents:: 2906
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA232760, UG1CA233373, W81XWH-18-1-0562 and -0563, W81XWH-16-1-0265 and 0266, BCRF-19-16, Bankhead-Coley Research Program (6BC05), Roche

Corr. Author:
Authors:: Saranya Chumsri Zhuo Li Daniel J. Serie Nadine Norton Afshin Mashadi-Hossein Kathleen Tenner Heather Ann Brauer Sarah Warren Patrick Danaher Gerardo Colon-Otero Ann H. Partridge Lisa A. Carey Florentine Hilbers Veerle Van Dooren Eileen Holmes Serena Di Cosimo Olena Werner Jens Bodo Huober Amylou C. Dueck Christos Sotiriou Cristina Saura Alvaro Moreno-Aspitia Keith L. Knutson Edith A. Perez E. Aubrey Thompson

Networks:: LAPS-MA036, LAPS-MN026, LAPS-NC007, NY021, PR028

Study
Multiple Studies, or Legacy Studies in Alliance Study:: NCCTG-N9831, NeoALTTO
Phases:: 3

Keywords:: Predictive markers, Breast cancer